Using an orally bioavailable compound, LYC-54143, we demonstrated that activation of RORγ with a synthetic agonist induced robust antitumor effects in MC38 and 4T1 tumor models in an immune cell-dependent fashion (Fig. 5). The gene discussed is RORC; the disease is neoplasm.